风险分层工具在接受免疫检查点抑制剂治疗的晚期黑色素瘤（AM）患者中缺乏。我们确定了一个与总生存期（OS）相关的新预后模型。该多中心回顾性队列研究收集了318名接受ICI治疗的治疗原始患者。 LASSO Cox回归确定了与OS相关的独立预后因子。在500个重复采样中进行了模型验证。 Harrel的C指数计算并进行内部验证以描述模型的判别能力。在后期行列的142名接受ICI治疗的晚期黑色素瘤患者中进行了外部验证。该模型包括高白细胞计数（WBC），高乳酸脱氢酶（LDH），低白蛋白，东方合作组织肿瘤学小组（ECOG）表现状况≥1和具有肝转移的情况。将患者分为3个风险组：良好（0-1个因子）OS为52.9个月，中间（2-3个因子）OS为13.0个月，差（≥4个因子）的OS为2.7个月。发现队列中的模型C指数为0.69。在治疗后期行列的外部验证（N = 142）示出了0.65的C指数。肝转移，低白蛋白，高LDH，高WBC和ECOG≥1可以结合成一个针对接受ICI治疗的AM患者的预后模型。©作者（们）2023。 由牛津大学出版社出版。

Risk stratification tools for patients with advanced melanoma (AM) treated with immune checkpoint inhibitors (ICI) are lacking. We identified a new prognostic model associated with overall survival (OS).A total of 318 treatment naïve patients with AM receiving ICI were collected from a multi-centre retrospective cohort study. LASSO Cox regression identified independent prognostic factors associated with OS. Model validation was carried out on 500 iterations of bootstrapped samples. Harrel's C-index was calculated and internally validated to outline the model's discriminatory performance. External validation was carried out in 142 advanced melanoma patients receiving ICI in later lines.High white blood cell count (WBC), high lactate dehydrogenase (LDH), low albumin, Eastern Cooperative Oncology Group (ECOG) performance status ≥1, and the presence of liver metastases were included in the model. Patients were parsed into 3 risk groups: favorable (0-1 factors) OS of 52.9 months, intermediate (2-3 factors) OS 13.0 months, and poor (≥4 factors) OS 2.7 months. The C-index of the model from the discovery cohort was 0.69. External validation in later-lines (N = 142) of therapy demonstrated a c-index of 0.65.Liver metastases, low albumin, high LDH, high WBC, and ECOG≥1 can be combined into a prognostic model for AM patients treated with ICI.© The Author(s) 2023. Published by Oxford University Press.